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Key messages
What is already known about this subject?
 ► ankylosing spondylitis is associated with increased 
mortality compared with general population mem-
bers of similar age.
 ► a highly increased risk of respiratory infections 
among patients with ankylosing spondylitis has 
been reported, and this may add to an increased risk 
of death.
What does this study add?
 ► Patients with ankylosing spondylitis did not exhibit 
an increased mortality or increased risk of readmis-
sion following hospitalisation with pneumonia.
 ► Furthermore, an initially elevated risk for pulmonary 
complications in patients with ankylosing spondylitis 
decreased over time.
How might this impact on clinical practice?
 ► reassuringly, current management of pneumo-
nia in patients with ankylosing spondylitis appears 
appropriate.
AbstrAct
Objective little is known about the prognosis of infections 
in patients with ankylosing spondylitis (as) compared 
with patients without as. The purpose of this study was to 
examine whether as is associated with poorer outcomes in 
patients who are hospitalised with pneumonia.
Methods in a population- based cohort study including 
patients with hospitalised pneumonia with and without 
as, we compared 90- day rates of mortality, all- cause 
readmission (90 days post- discharge) and pulmonary 
complications including pulmonary embolism, empyema 
and pulmonary abscess. We used cox regression analyses 
to compute crude and adjusted hrs while adjusting for 
sex, age and level of comorbidity.
Results a total of 387 796 patients (median age 71 years) 
were hospitalised for pneumonia in Denmark between 
1997 and 2017. among these, 842 (0.2%) had as (median 
age 65 years). The 90- day mortality was 12.5% in patients 
with as and 15.5% in patients with non- as pneumonia, 
with crude and adjusted 90- day hrs of 0.79 (95% ci 0.66 
to 0.96) and 0.95 (95% ci 0.79 to 1.16), respectively. The 
90- day post- discharge readmission rate was 27.3% in 
patients with as and 25.4% in patients without as, with 
a corresponding adjusted readmission hr of 1.12 (95% 
ci 0.98 to 1.27). relative risk of pulmonary complications 
among patients with as compared with patients without as 
decreased over the study period, with adjusted hrs of 1.63 
(95% ci 0.82 to 3.27) in 1997–2006 falling to 0.62 (95% 
ci 0.31 to 1.23) in 2007–2017.
Conclusions as is not associated with increased mortality 
following hospitalisation for pneumonia. Furthermore, no 
increased risk of readmission or pulmonary complications 
in patients with as was detected in recent study years.
InTROduCTIOn and aIMs
Ankylosing spondylitis (AS) is a chronic 
inflammatory rheumatic disease often diag-
nosed in young age and with average age 
at disease onset of 24.8 years.1 AS is asso-
ciated with increased mortality compared 
with general population members of similar 
age.2 3 Previous studies have found this fact 
to be related to an increased cardiovascular 
and cerebrovascular mortality, but also to 
an increased risk of death from infections 
including respiratory tract infections.4 5
A highly increased risk of respiratory infec-
tions among patients with AS was reported 
(OR 5.83, 95% CI 3.38 to 10.1) in a German 
study comparing the cumulative prevalence 
of self- reported infections in the previous 12 
months among 1080 patients with AS and 102 
patients with disc herniation.6 In contrast, 
little is known about the prognosis of infections 
in patients with AS compared with members 
of the general population without AS. It there-
fore remains unclear if the increased risk of 
dying from respiratory and other infections 
in AS can be explained solely by an increased 
risk of acquiring infections, or if patients with 
AS have worse infection outcomes as well.
Pneumonia remains a common cause 
of morbidity and mortality worldwide. A 
study from 2013 showed that pneumonia 
hospitalisations in Denmark increased from 
4.96/1000 population in 1997 to 8.09 in 
2011. The mortality following hospitalised 
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Table 1 Characteristics of patients with and without 
ankylosing spondylitis (AS) who were hospitalised for 
pneumonia from 1997 to 2016 in Denmark
AS
N (%)
Non- AS
N (%)
N 842 (0.2) 386.954 (99.8)
Age, median (IQR) 65 (52–74) 71 (57–81)
  16–29 years 22 (2.6) 15.965 (4.1)
  30–44 years 102 (12.1) 35.690 (9.2)
  45–59 years 195 (23.2) 58.375 (15.1)
  60–74 years 316 (37.5) 111.667 (28.9)
  75 years and above 207 (24.6) 165.247 (42.7)
Sex
  Female 218 (25.9) 190.532 (49.2)
  Male 624 (74.1) 196.422 (50.8)
Pneumonia 1997–2006 274 (0.2) 161.597 (99.8)
Pneumonia 2006–2017 568 (0.3) 224.500 (99.7)
Comorbidity within 10 years before pneumonia
  Congestive heart failure 97 (11.5) 30.946 (8.0)
  Peripheral vascular disease 66 (7.8) 26.598 (6.9)
  Previous myocardial 
infarction
48 (5.7) 20.386 (5.3)
  Chronic pulmonary disease 152 (18.1) 60.981 (15.8)
  Cerebrovascular disease 91 (10.8) 48.986 (12.7)
  Hemiplegia 19 (2.7) 1.917 (0.5)
  Dementia 7 (0.8) 13.304 (3.4)
  Connective tissue disease 79 (9.4) 9.834 (2.5)
  Peptic ulcer disease 54 (6.4) 17.479 (4.5)
  Diabetes type I and II 77 (9.1) 30.399 (7.8)
  Diabetes with end organ 
damage
46 (5.5) 17.004 (4.4)
  Moderate to severe renal 
disease
45 (5.3) 13.961 (3.6)
  Any tumour 98 (11.6) 52.629 (13.6)
  Leukaemia 5 (0.6) 3.484 (0.9)
  Lymphoma 13 (1.5) 6.205 (1.6)
  Metastatic solid tumour 18 (2.1) 9.365 (2.4)
  Mild liver disease 16 (1.9) 5.636 (1.5)
  Moderate- to- severe liver 
disease
2 (0.2) 1.72 (0.45)
  AIDS 0 545 (0.1)
Comorbidity index (level of Charlson Index Score)
  Low (0) 350 (41.6) 180.629 (46.8)
  Medium (1–2) 316 (37.5) 137.850 (35.7)
  High (≥3) 176 (20.1) 67.934 (17.6)
Duration of hospital stay in 
days, median (IQR)
6 (3–11.5) 7 (4–12)
pneumonia is high and seems largely unchanged over 
decades.7 To date, no population- based pneumonia 
cohort outcome study has focused on patients with AS.
Pre- existing lung disease is associated with poorer 
outcomes after pneumonia.8 9 Studies have reported 
that lung disease including apical fibrosis, interstitial 
lung disease and chest wall abnormalities are associated 
with AS, and that chronic obstructive pulmonary disease 
(COPD) is more frequent among patients with AS than 
controls.10 11 Moreover, inflammatory disease activity and 
AS- related therapy might influence pneumonia outcomes.
We hypothesised that AS is associated with increased 
mortality, risk of complications and readmission in 
patients who are hospitalised with pneumonia. In addi-
tion, we wanted to explore if relative risks of these 
outcomes decreased over time in patients with AS versus 
patients without AS, and if AS disease activity and AS 
therapy influence the pneumonia prognosis.
PaTIenTs and MeTHOds
setting and study population
We conducted a population- based cohort study in Denmark 
with approximately 5.8 million inhabitants. All Danish citi-
zens are assigned a unique personal identification number 
(CPR) at birth or immigration which we used to cross- link 
data from different medical registries at the individual 
level.12 We used the Danish National Patient Register 
(DNPR) to identify patients with pneumonia. Since 1977, 
the DNPR has recorded all inpatient hospitalisations in the 
entire Danish population and since 1995 all instances of 
contact with hospital outpatient clinics. The DNPR records 
admission and discharge dates and up to 20 discharge diag-
noses per contact coded according to the International 
Classification of Diseases, edition 10 (ICD-10) during the 
period of this study and ICD-8 during earlier periods.13 The 
records also include CPR numbers, patients’ municipalities, 
identification of the hospital wards, and dates and times of 
activities performed, including information on the type of 
examinations, surgeries and treatments. We included all 
adult patients (≥16 years) with a first- time primary hospital 
discharge diagnosis of pneumonia (for ICD-10 codes, 
please see online additional file 1) between January 1997 
and 31 July 2017; thus, patients with a prior discharge diag-
nosis of pneumonia were excluded. A previous evaluation 
of the validity of the pneumonia diagnosis in DNPR found 
a positive predictive value (PPV) of 90% (95% CI 82% to 
95%).14
data on as
Data on AS were obtained from the DNPR and DANBIO 
(for ICD codes, please see online additional file 1). While 
DANBIO contains information on subcohorts of patients 
with AS, all patients with AS seen in hospital clinics are 
registered in the DNPR. DANBIO is a nationwide, Danish 
register where clinical data on patients with rheumatic 
diseases are recorded. DANBIO was initiated in 2000 as a 
nationwide voluntary register, and in 2006 DANBIO was 
approved by the Danish National Board of Health as a 
national quality of care registry.15 Since then, it has been 
mandatory to register all patients with AS on biologics and 
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Table 2 90- day all- cause mortality following hospitalisation with pneumonia in patients with or without ankylosing spondylitis 
(AS)
All- cause mortality at 90 days N (%) HRs 90- day mortality
AS Non- AS
Crude Adjusted*
AS AS
All patients hospitalised for 
pneumonia 1997–2017†
105 (12.5) 59.767 (15.5) 0.79 (0.66 to 0.96) 0.95 (0.79 to 1.16)
  1997–2006 38 (13.9) 25.208 (15.6) 0.88 (0.64 to 1.21) 1.03 (0.75 to 1.41)
  2007–2017† 67 (11.8) 34.559 (15.4) 0.76 (0.59 to 0.96) 0.94 (0.74 to 1.20)
HRs, including 95% CIs, calculated using Cox proportional- hazards regression analysis. Patients without AS used as reference group.
*Adjusted for sex, age and level of comorbidity before admission.
†Until 31 July 2017.
since 2015 all newly diagnosed patients with AS. Patients are 
registered in DANBIO, when they are seen by a rheumatol-
ogist in hospital or private outpatient clinics. The recorded 
information includes the current treatment, disease activity 
(see below), C reactive protein, functional status and visual 
analogue scale scores of pain, fatigue, and of the patient 
and physician’s global assessment.
data on disease activity and functional status
We obtained information on the latest registration of 
the Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI) from DANBIO. BASDAI combines informa-
tion on morning stiffness, localised tenderness, fatigue 
and joint pain (reference), and in Denmark a score above 
4 usually indicates that the patient is a candidate for treat-
ment with biologics. The BASDAI has a good test–retest 
(r=0.93; p<0.001) reliability, reflects the entire spectrum 
of disease and is sensitive to change.16
We used the Bath AS Functional Index (BASFI) as a 
measure of the patient’s functional limitation and the 
Bath AS Metrology Index (BASMI) as a measure of the 
patient’s axial status. BASMI has been found repro-
ducible for both intraobserver (r=0.99, p<0.001) and 
interobserver variability (r=0.97, p<0.001) and sensitive 
to change.17 BASFI has been shown as a reliable tool 
in assessing function in patients with AS and is able to 
capture changes across the whole spectrum of disease.18
data on medication
Data on AS treatment were assessed from both DNPR 
and DANBIO.15 In the DNPR, treatment with disease- 
modifying antirheumatic drugs (DMARDs) and biologics 
are coded in relation to visits at hospital outpatient 
clinics. For AS outpatient visits, the use and types of 
DMARDs and/or biologics are recorded. We retrieved 
DNPR information on all treatments registered within 
12 months prior to pneumonia hospitalisation. For the 
subgroup of patients with pneumonia who were regis-
tered in the DANBIO database, we also retrieved infor-
mation from the last visit within 12 months before the 
pneumonia hospitalisation. If the patient had more than 
one registration in DANBIO within that year, the latest 
visit data were used.
We categorised all patients with AS according to the type 
of preadmission AS medication into the following groups: 
treatment with DMARD (either as monotherapy or as 
DMARD combination therapy), anti- TNF alfa treatment as 
monotherapy, anti- TNF alfa treatment in combination with 
one or more DMARDs, and no recorded AS therapy. The 
patients were categorised according to the last registered 
treatment type before the pneumonia hospitalisation.
Comorbidity data
We obtained information on the 19 conditions included 
in the Charlson Comorbidity Index recorded within 10 
years before the pneumonia hospitalisation from the 
DNPR. A previous study found the coding in the DNPR 
for the 19 Charlson conditions to have an overall PPV of 
98%.19 In addition, the index has previously been vali-
dated as a predictor of 1- year mortality following hospital-
isation.20 21 We did not include the AS diagnosis when we 
computed the Charlson Comorbidity Index score, and 
we categorised the scores into three levels: score of 0, low; 
score of 1–2, medium; score of 3+, high.
Pneumonia outcomes
Death from any cause within 90 days from the pneu-
monia hospitalisation was a main study outcome. We 
ascertained the exact date of eventual death from the 
Danish Civil Registration System.12 Other outcomes were 
all- cause readmission rate within 90 days after initial 
pneumonia hospitalisation discharge, and hospital diag-
noses of pulmonary complications associated with the 
initial hospitalisation or up to 90 days after the admis-
sion date. We defined complications as pulmonary embo-
lism, empyema or pulmonary abscess (please see online 
supplementary appendix for ICD-10 codes). Information 
on both readmission and pulmonary complications were 
obtained from the DNPR.
statistical analysis
Pneumonia prognosis in patients with as versus patients without 
as
We followed all patients with pneumonia from the date 
of pneumonia admission until death, migration or 90 
days after the discharge date, whichever came first. We 
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estimated mortality, rates for readmission and pulmo-
nary complications after 90 days for patients with AS and 
patients without AS. Cox regression was used to compute 
crude and adjusted HRs for death, readmission and 
pulmonary complications within 90 days following admis-
sion for pneumonia while comparing patients with AS 
and those without AS, controlling for age, sex and level 
of comorbidities. In order to evaluate if the prognostic 
impact of AS on pneumonia changed over time, we strat-
ified the analysis by calendar time for pneumonia diag-
nosis (1997–2006 and 2007–2017).
Prognostic effect of as disease activity and therapy among 
patients with as
Internally among patients with pneumonia with AS, we 
compared 90- day mortality between high and low levels 
of preadmission BASDAI (reference: BASDAI <4), BASFI 
(reference: BASFI <4) and BASMI (reference BASMI 
<4). We also compared 90- day mortality associated with 
the different treatment categories, using ‘no treatment’ 
as reference. We used Cox regression while adjusting for 
sex, age and level of comorbidities.
Statistical analyses were performed using the Stata 
V.12.1 statistical software package (StataCorp, College 
Station, TX, USA). We presented HRs as point estimates 
with 95% CIs.
ResulTs
A total of 387 796 patients were hospitalised for pneu-
monia between 1997 and 2017. Among these 842 (0.2%) 
had AS. As expected, the proportion of men was higher 
among patients with AS (74.1%) than among patients 
without AS (50.8%) (table 1). Patients with AS were 
younger (median age 65 vs 71 years) and had higher 
comorbidity including higher prevalence of chronic lung 
disease. Among patients with AS, 57.6% had one or more 
comorbidities compared with 53.3% among patients 
without AS. The median duration of hospital stay for 
patients with AS was 6(3-15) days compared with 7(4-12) 
days for patients without AS.
Mortality in patients with as versus patients without as
We found a 90- day mortality in patients with pneumonia 
with AS of 12.5% compared with 15.5% in patients with 
non- AS pneumonia. Corresponding crude 90- day HR was 
0.79 (95% CI 0.66 to 0.96). After adjustment for differ-
ences in age the HR increased to 1.07 (95% CI 0.88 to 
1.29), and with further adjustment for sex and comor-
bidity, the HR was 0.95 (95% CI 0.79 to 1.16) (table 2).
Among patients without AS, the 90- day pneumonia 
mortality remained steady across the two calendar 
periods with rates of 15.6% and 15.4%, while the 90- day 
mortality in patients with AS tended to be highest in the 
first period with a rate of 13.9% compared with 11.8% in 
the second period. When comparing the 90- day mortality 
between patients with AS and patients without AS, we 
found adjusted HRs of 1.03 (95% CI 0.75 to 1.41) in the 
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Table 4 Characteristics of patients with ankylosing 
spondylitis who were hospitalised for pneumonia from 1997 
to 2016 in Denmark and registered in DANBIO
Registration in 
DANBIO at any 
time prior to the 
hospitalisation for 
pneumonia
Registration in 
DANBIO 0–12 
months prior to the 
hospitalisation for 
pneumonia
N 185 133
Age, median (IQR) 53.8 (43–65) 52.2 (42–62)
  16–29 years (%) 10 (5.4) 6 (4.5)
  30–44 years (%) 44 (23.8) 34 (25.6)
  45–59 years (%) 60 (32.4) 52 (39.1)
  60–74 years (%) 56 (30.3) 33 (24.8)
  75 years and above 15 (8.1) 8 (6.0)
Sex
  Female (%) 54 (29.2) 38 (28.6)
  Male (%) 131 (70.8) 95 (71.4)
Year of pneumonia hospitalisation
  1997–2006 8 8
  2006–2017 177 125
Comorbidity index (Charlson Index Score)
  Low (0) 103 (55.7) 80 (60.2)
  Medium (1–2) 54 (29.2) 35 (26.3)
  High (≥3) 28 (15.1) 18 (13.5)
Patients with BASDAI 
available (%)
148 (80.0) 110 (82.7)
  BASDAI <4 (% of 
available)
66 (44.5) 51 (46.4)
Patients with BASFI 
available (%)
146 (78.9) 109 (82.0)
  BASFI <4 (% of 
available)
62 (42.5) 52 (47.7)
Patients with BASMI 
available (%)
95 (51.4) 70 (52.6)
  BASMI <4 (% of 
available)
49 (51.7) 39 (55.7)
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, 
Bath AS Functional Index; BASMI, Bath AS Metrology Index.
first period 1997–2006 and 0.94 (95% CI 0.74 to 1.20) in 
the second period 2007–2017.
Readmission and pulmonary complications in patients with 
as versus patients without as
Among the patients with AS, 27.3% were readmitted 
within 90 days after discharge compared with 25.4% of 
the patients without AS. The corresponding crude 90- day 
post- discharge HR for readmission was 1.08 (95% CI 0.95 
to 1.22), and the adjusted HR was 1.12 (95% CI 0.98 
to 1.27). The readmission rate among patients with AS 
patients was slightly lower in the second period (26.8%) 
than in the first (28.5%) (table 3), resulting in adjusted 
HRs of readmission associated with AS of 1.15 (95% CI 
0.92 to 1.44) in the first period and 1.05 (95% CI 0.89 
to 1.23) in the second period. The risk of pulmonary 
complications among patients with AS compared with 
patients without AS decreased more clearly over time, 
with adjusted HRs of complications for the first and 
second periods of 1.63 (95% CI 0.82 to 3.27) and 0.62 
(95% CI 0.31 to 1.23), respectively.
Prognostic effect of as functional status, disease activity and 
therapy
Prior to admission, 185 (22%) of the patients with AS 
had at least one registration in DANBIO. In 133 patients, 
the last registration was within 1 year prior to admission 
(table 4). The proportion of men was 70.8%, similar to 
the entire cohort, while the patients in DANBIO were 
slightly younger than in the entire cohort of patients with 
AS with a median age of 55 (43–65).
BASDAI measurements within 1 year prior to admis-
sion were available for 110 patients. Compared with 
the group with low BASDAI (<4), we found crude and 
adjusted 90- day HR for mortality with BASDAI >4 of 1.00 
(95% CI 0.95 to 1.05) and 0.99 (95% CI 0.94 to 1.05), 
respectively. BASFI measurements were available for 109 
patients. Compared with the group with low BASFI (<4), 
crude and adjusted 90- day HR for mortality with BASFI 
>4 were 1.03 (95% CI 0.97 to 1.08) and 1.02 (95% CI 0.96 
to 1.09), respectively. BASMI measurements were avail-
able for 70 patients. Compared with the group with low 
BASMI (<4), we found crude and adjusted 90- day HR for 
mortality with BASMI >4 of 1.01 (95% CI 0.96 to 1.06) 
and 0.99 (95% CI 0.94 to 1.05), respectively.
Among the patients with AS, 18 (2%) were treated with 
one or more DMARDS, 87 (10.3%) were treated with 
anti- TNF alfa monotherapy and 44 (5.2%) received a 
combination of anti- TNF alfa and DMARDs. Among non- 
treated patients, 68% were 60 years or older compared 
with patients treated with either anti- TNF alfa mono-
therapy or in combination with DMARDs, of which 33% 
and 27% were 60 years or older, respectively. Among 
patients treated with DMARDs, 55% were 60 years or 
older and in this group 50% were women—while in all 
other groups approximately 70% were men. The 90- day 
mortality was higher among non- treated (13.6%) than 
patients treated with DMARD (5.6%), anti- TNF (5.8%) 
or anti- TNF alfa and DMARD in combination (6.8%), 
respectively. The low number of exposed hampered 
our ability to adjust for potential confounding factors. 
Neither anti- TNF alfa monotherapy, treatment with 
DMARDs nor anti- TNF alfa therapy in combination with 
one or more DMARDS were associated with increased 
mortality (table 5).
dIsCussIOn
In this population- based study including 842 patients 
with AS and more than 350 000 patients without AS 
hospitalised due to pneumonia, patients with AS did 
not have higher mortality, complications and readmis-
sion rates than patients without AS after adjustment for 
confounding factors.
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Table 5 All- cause mortality in patients with AS following hospitalisation for pneumonia according to preadmission as therapy
N
All- cause mortality 
at 90 days, N (%)
HRs 90- day mortality
Crude Adjusted*
No DMARD, no anti- TNF alfa 693 96 (13.6) 1 (ref) 1 (ref)
DMARD 18 1 (5.6) 0.39 (0.05 to 2.77) 0.52 (0.07 to 3.76)
Anti- TNF alfa 87 5 (5.8) 0.64 (0.41 to 1.00) 0.95 (0.60 to 1.51)
Anti- TNF alfa and DMARD combination 44 3 (6.8) 0.78 (0.53 to 1.14) 1.01 (0.69 to 1.49)
HRs, including 95% CIs, were calculated using a Cox proportional- hazards model.
*Adjusted for sex, age and level of comorbidity before admission.
AS, ankylosing spondylitis; DMARD, disease- modifying antirheumatic drug; TNF, tumour necrosis factor.
Lung disease is associated with AS. This includes chronic 
apical fibrosis, interstitial lung disease and chest wall 
abnormalities.10 11 A recent study from Israel including 
4076 patients with AS and 20 290 age- matched and sex- 
frequency- matched controls found a higher proportion 
of COPD in patients with AS than in controls (46% vs 
18%).11 We found only a slightly higher prevalence of 
COPD among our patients with AS than in the patients 
with non- AS pneumonia (18% vs 15%), but no increased 
crude pneumonia mortality versus non- AS individuals. In 
the study from Israel, the diagnoses of COPD is based on 
data derived from both hospital and primary care physi-
cians’ clinical records, while our study included records 
from hospitals and not primary care physicians. It is likely 
that patients with one chronic disease like AS are more 
likely to see their physician on a regular basis and there-
fore more likely to be diagnosed with COPD even in case 
of very mild symptoms. This is in contrast to patients 
either referred to hospital with COPD or diagnosed with 
COPD at hospitals, who are more likely to suffer from 
more severe COPD.
The AS pneumonia mortality was slightly higher in the 
first half of our study period (1997–2006) than in the 
second period (2007–2017). This may be partly caused 
by the fact that predominantly patients with AS with 
severe AS disease were seen at hospitals in the beginning 
of our study period and thus registered with a diagnosis 
of AS in the DNPR. In the second period (2007–2017), 
biologics were commonly used for AS and the new treat-
ment strategies likely resulted in patients with AS being 
more commonly hospital registered, but also treated 
more efficiently. It is also possible that prednisolone was 
used more frequently in the first period and that this may 
have affected the outcome following pneumonia. Unfor-
tunately, we lacked information on use of prednisolone 
so we could not address this any further.
The strengths of this study include the accuracy and 
the size of the data sources used. Complete follow- up data 
from detailed, high- quality registries allowed for exten-
sive control of confounders. Both selection and recall 
bias were limited because of the prospectively recorded 
population- based data independently of our research 
question. We were able to adjust for a broad range of 
comorbidities using the Charlson Index, but not for life-
style factors, such as smoking and body mass index. Since 
smoking is a major contributor to the risk and severity 
of COPD, the patients with AS might be more likely to 
be smokers, but the proportion of patients with AS with 
COPD was only slightly increased and this could not have 
substantially affected our results.
The identification of patients with AS through the 
DNPR may have excluded patients with AS with mild 
disease (ie, patients who were never treated at a hospital 
clinic or were admitted for another illness only without 
concomitant registration of AS in the DNPR). There is, 
however, no reason to suspect that their mortality should 
be higher following pneumonia hospitalisation than 
those of the patients with AS that we captured by our data 
sources.
Patients with AS receiving DMARDs and/or anti- TNF 
alfa therapy are closely monitored in the outpatient clinic 
and may be hospitalised earlier and/or more frequently 
in case of suspected infection than patients being 
managed without these treatments. Accordingly, at time 
of pneumonia hospitalisation, patients with AS receiving 
DMARDs and/or anti- TNF alfa therapy may be less seri-
ously affected by the pneumonia which may result in a 
lower mortality.
Neither anti- TNF alfa monotherapy, treatment 
with DMARDs, nor anti- TNF alfa therapy in combina-
tion with one or more DMARDS were associated with 
increased pneumonia mortality in this study. However, 
the low number of drug- exposed patients and outcome 
events hampered our ability to adjust for all potential 
confounding factors, and these results should be inter-
preted with caution.
Patients with AS with high disease activity, decreased 
functional status or poorer axial status could have a 
poorer outcome of pneumonia than the average patient 
with AS. DANBIO data allowed us to identify patients with 
AS who potentially had high disease activity, decreased 
functional status and poor axial status at time of pneu-
monia diagnosis. We thus find it reassuring that these 
patients did not have high mortality following pneu-
monia, even if they only represent a minor part of the AS 
study population.
Recent studies have indicated that non- steroidal 
anti- inflammatory drug (NSAID) exposure at the early 
stage of community- acquired pneumonia is associated 
with a more complicated course and worse outcomes, 
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probably because NSAIDs mask initial symptoms and 
delay therapy.22 23 It is likely that a large proportion of 
patients with AS in our study received NSAIDs since 
NSAIDs are first- line treatment in AS. Unfortunately, 
we lacked information on use of NSAIDs, and we were 
thus unable to examine whether pneumonia prognosis 
varied by use of these drugs. However, we did not find 
an increased mortality among patients with AS compared 
with patients without AS, which makes it unlikely that 
NSAID causes significantly increased mortality among 
patients with AS following pneumonia.
Conclusions
Despite the well- known association between AS and lung 
disease, our study, to our knowledge, is the first to investi-
gate the influence of AS on the prognosis of pneumonia. 
Reassuringly, we found no increased pneumonia mortality 
among patients with AS. In addition, no increased risk of 
pneumonia complications or readmission was detected 
in patients with AS in recent years.
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